Halting metastasis through CXCR4 inhibition

Bioorg Med Chem Lett. 2013 Jan 1;23(1):20-5. doi: 10.1016/j.bmcl.2012.10.138. Epub 2012 Nov 12.

Abstract

Metastasis occurs when cancer cells leave the primary tumor site and migrate to distant parts of the body. The CXCR4-SDF-1 pathway facilitates this migration, and its expression has become the hallmark of several metastatic cancers. Targeted approaches are currently being developed to inhibit this pathway, and several candidates are now in clinical trials. Continued exploration of CXCR4 inhibitors will generate compounds that have improved activity over current candidates.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antineoplastic Agents / therapeutic use*
  • Binding Sites
  • Chemokine CXCL12 / antagonists & inhibitors
  • Chemokine CXCL12 / metabolism
  • Clinical Trials as Topic
  • Heterocyclic Compounds / chemistry
  • Heterocyclic Compounds / therapeutic use*
  • Humans
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Metastasis / pathology*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Peptides / metabolism
  • Receptors, CXCR4 / antagonists & inhibitors*
  • Receptors, CXCR4 / metabolism
  • Single-Domain Antibodies / immunology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • CXCL12 protein, human
  • Chemokine CXCL12
  • Heterocyclic Compounds
  • Peptides
  • Receptors, CXCR4
  • Single-Domain Antibodies
  • plerixafor octahydrochloride